Clinical Observation Of Beinaglutide Combined With CS? In The Treatment Of Type 2 Diabetes With Metabolic Syndrome

Objective:Observe and analyze the effects of beinaglutide combined with CSII on various clinical indicators in the treatment of type 2 diabetes and metabolic syndrome,evaluate its effectiveness and safety,and provide evidence-based medical proof for clinical treatment of type 2 diabetes with metabolic syndrome.Method:From December 2017 to May 2019,patients with type 2 diabetes and metabolic syndrome who met the enrollment criteria in the Department of Endocrinology,the second hospital of Jilin University were collected.The patients were randomly divided into three groups,named A,B,C group,A and B group as the experimental group,C group as the control group.Group A was given continuous subcutaneous injection of beinanlutide combined with insulin pump(0.1 mg three times daily subcutaneously 5 minutes before meals).The initial dosage of beinanlutide was adjusted to 1-2 weeks(0.2 mg three times daily subcutaneously 5 minutes before meals).In group B,benalutide and insulin were injected subcutaneously for 5 minutes before meals three times a day.Group C received continuous subcutaneous injection of insulin pump.All three groups were given a diabetic diet,moderate exercise,and timely adjusted insulin dosage according to blood glucose levels,so that all patients in the three groups were discharged after reaching the standard.After discharge,group A continued to receive beinaglutide(0.2 mg three times daily subcutaneously before meals)Combined with insulin treatment,group B continued to receive beinaglutide(0.1 mg three times daily subcutaneously 5 minutes before meals)combined with insulin treatment,and group C was treated with insulin.Three groups of patients were treated for 24 weeks.The indexes before and after treatment were recorded,including fasting blood glucose,2 hours postprandial blood glucose,glycated hemoglobin A1 c,triglycerides,total cholesterol,high-density lipoprotein cholesterol,low-density lipoprotein cholesterol,fasting insulin,insulin resistance index,fasting C peptide,2 hours postprandial C peptide,C peptide increase,Body Mass Index,waist circumference,weight,blood pressure,incidence of hypoglycemia,incidence of adverse reactions.Result:This study intends to collect 90 patients,4 of whom were withdrawn for different reasons,and 86 patients were finally followed up,including 28 patients in group A,29 patients in group B,and 29 patients in group C.Three groups of related clinical data were collected at 24 weeks index;There was no significant difference between the three groups in general clinical data and various examination indexes before treatment(P > 0.05).The FPG,2hPG,and HbA1 c of the three groups of patients decreased at 24 weeks and before treatment(p <0.05),and there was a statistical difference between the three groups at 24 weeks(p <0.05).The BMI,weight,and waist circumference of the patients in group A and group B decreased at 24 weeks and before treatment(p <0.05),and compared with group B,they were significantly decreased at 24 weeks(p <0.05).There was no statistical difference in BMI,body weight,and waist circumference between patients in group C at 24 weeks and before treatment(p> 0.05).The TG,TC,and LDL-C of the three groups of patients decreased at 24 weeks of treatment compared with those before treatment(p <0.05).The TG and LDL-C were statistically different between the three groups at 24 weeks of treatment(p <0.05).0.05);TC was compared between the three groups at 24 weeks of treatment.There was a statistically significant difference between group A and C(p <0.05),and a statistically significant difference between group B and group C(p <0.05).There was no significant difference between groups B(P> 0.05).The HDL-C levels of the three groups of patients increased at 24 weeks of treatment compared with before treatment(p <0.05);the HDL-C levels of patients in group A and C were statistically different at 24 weeks of treatment(p <0.05),there was no significant difference between group A and group B,group B and group C at 24 weeks of treatment(p> 0.05);The HOMA-IR of the three groups of patients decreased at 24 weeks of treatment compared with that before treatment(p <0.05),and there was a statistically significant difference between the three groups at 24 weeks of treatment(p <0.05).The FCP of patients in group A decreased compared with that before treatment at 24 weeks(p <0.05).The FCP of patients in group B and group C had no statistical difference when compared with before treatment at 24 weeks(p> 0.05).The 2hCP of patients in group A and group B increased at 24 weeks and before treatment(p <0.05),and there was a statistical difference between group A and group B at 24 weeks of treatment(p <0.05).There was no statistical difference in the 2hCP of patients in group C at 24 weeks of treatment compared with that before treatment(p> 0.05).The ?CP of patients in group A and group B increased at 24 weeks and before treatment(p <0.05),and there was a statistical difference between group A and group B at 24 weeks of treatment(p <0.05).There was no statistical difference in the ?CP of group C patients at 24 weeks after treatment compared with before treatment(p> 0.05).The systolic blood pressure and diastolic blood pressure of patients in group A and group B were lower than those before treatment at 24 weeks(p <0.05).There was no statistical difference between group A and group B at 24 weeks of treatment(p> 0.05).There was no statistical difference in systolic blood pressure and diastolic blood pressure between patients in group C and 24 weeks before treatment(p> 0.05).The incidence of adverse reactions in group A and group B was higher than that in group C(P < 0.05).The incidence of adverse reactions during the treatment of the three groups was compared between groups.The incidence of adverse reactions during the treatment of group A and group B was higher than that of group C,with statistical differences(p <0.05).Conclusions: 1?In the treatment of type 2 diabetes mellitus patients with metabolic syndrome,benalutide can significantly reduce blood glucose,weight loss,improve the disorder of blood lipid metabolism,reduce insulin resistance,repair the function of insulin ? cell,and reduce blood pressure,especially in the aspect of weight loss and insulin resistance improvement,which has better safety and is not easy to appear hypoglycemia.2?In the course of treatment,benalutide is dose-dependent.The maximum dose of benalutide has a better therapeutic effect,which can further reduce body weight,repair the function of islet ?-cell,and improve insulin resistance.